13 hasil untuk "A. Cellini"
Menampilkan 1–13 · 0,53 detik · RSS
-
Artikel Jurnal
DP047 | A SINGLE CENTER EXPERIENCE OF FIXED DURATION THERAPY IN 108 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
Background. The current treatment strategies for patients (pts) with chronic lymphocytic leukemia (CLL) include a continuous BTK inhibitor (BTKi) or a fixed-duration therapy (FDT) with combinations of target agents (BTKi and/or venetoclax [VEN] and/or antiCD20 monoclonal antibodies [mAb]). However…
-
Artikel Jurnal
DP050 | ASSESSING THE IMPACT OF COMORBIDITIES IN HAIRY CELL LEUKEMIA: VALIDATION OF THE CLL-CI/TRES SCORE IN PATIENTS TREATED WITH PURINE ANALOGUES
Introduction Hairy cell leukemia (HCL) is an indolent disease that enjoys excellent response and durable remissions after therapy with the purine analogues (PAs) cladribine (2CDA) and pentostatin (DCF). Yet, the impact of different comorbidities on HCL outcomes is still unknown, and no standardized…
-
Artikel Jurnal
DP055 | DISTINCT RELAPSE PATTERNS IN CHRONIC LYMPHOCYTIC LEUKEMIA AFTER THERAPY WITH BTK OR BCL2 INHIBITORS
Introduction Bruton tyrosine kinase inhibitors (BTKi) and venetoclax exert their effect on two different populations of chronic lymphocytic leukemia (CLL) cells: while BTKi act on the dividing subpopulation of CLL cells, which is killed after mobilization from the lymph nodes into the circulation…
-
Artikel Jurnal
DP054 | INFECTIONS, SECOND PRIMARY MALIGNANCIES AND AUTOIMMUNE DISEASES IN MONOCLONAL B-CELL LYMPHOCYTOSIS AND EARLY-STAGE CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHTS FROM A RETROSPECTIVE COHORT OF A TERTIARY CARE CENTRE
Background. Monoclonal B-cell Lymphocytosis (MBL) is a premalignant phase of Chronic Lymphocytic Leukemia (CLL), defined by less than 5x10^9 clonal B-cells/L in the peripheral blood of otherwise healthy individuals. MBL is further classified into low-count (LC-MBL) (< 0.5x10^9 clonal B-cells/L) and…
-
Artikel Jurnal
P043 | TRANSPLANT-FREE APPROACHES IN REFRACTORY CLASSICAL HODGKIN LYMPHOMA: A SINGLE CENTRE STUDY
Background. Autologous stem-cell transplantation (ASCT) represents the main approach for refractory classical Hodgkin Lymphoma (HL). Although often curative, this procedure is frequently hindered by short- and long-term toxicities. In recent years, novel drugs such as Checkpoint Inhibitors (CPI)…
-
Artikel Jurnal
C060 | UNRAVELING THE AGGRESSIVENESS OF ACCELERATED CLL THROUGH SINGLE-CELL TRANSCRIPTOMICS AND GENOMIC PROFILING
Introduction Accelerated chronic lymphocytic leukemia (aCLL) is a yet understudied entity consisting of CLL with specific aggressive histological features that likely falls in the biological spectrum between CLL and Richter’s transformation (RT). In this study, we aimed to shed light on the…
-
Artikel Jurnal
C031 | 10-YEAR UPDATE OF THE HD0607 STUDY ON ADVANCED-STAGE HODGKIN LYMPHOMA. FOCUS ON LONG-TERM RESPONSES AND LATE TOXICITIES.
Background. The HD0607 clinical trial contributed significantly to establishing the PET/CT-guided escalation approach in patients with advanced-stage (IIB-IV) classical Hodgkin lymphoma (HL). As our approach to advanced-stage HL improves and higher cure rates are achieved, late therapy-related…
-
Artikel Jurnal
P015 | FEATURES AND OUTCOMES OF ASYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA IN RELATION TO BONE MARROW INFILTRATION: AN ITALIAN UNIVERSITY HOSPITAL ANALYSIS
Studies have suggested that the size of the bone marrow neoplastic lymphoplasmacytic infiltrate holds prognostic value for the time to progression from asymptomatic to symptomatic Waldenstrom Macroglobulinemia (WM). We conducted an analysis on 230 patients with WM diagnosed (2005-2025) at the…
-
Artikel Jurnal
P029 | SECONDARY HYPOGAMMAGLOBULINEMIA IN NON-HODGKIN LYMPHOMAS: INCIDENCE, RISK FACTORS, AND CLINICAL IMPACT
The most frequent form of secondary immunodeficiency (SID) is secondary hypogammaglobulinemia (SAD), commonly caused by B-cell non-Hodgkin lymphomas (NHL) and their treatments. SAD is diagnosed by low serum IgG levels: mild-moderate (4–6 mg/dL) and severe (
-
Artikel Jurnal
DP040 | NOVEL GENETIC VARIANTS AND OLIGOGENIC MECHANISMS IN IDIOPATHIC ERYTHROCYTOSIS: A TARGETED NEXT-GENERATION SEQUENCING APPROACH
Idiopathic erythrocytosis (IE) includes a heterogeneous group of disorders defined by increased red cell mass without secondary causes or known clonal mutations. While advances in molecular diagnostics have uncovered variants in genes related to oxygen sensing, erythropoietin signaling, iron…